Skip to main content
PRCTPROCEPT BioRobotics CorporationSell5.8·$16.80-4.27%
PRCT · Concentration risk · 10-K extracted

PROCEPT BioRobotics (PRCT) concentration risks

Updated

The most significant concentration PROCEPT BioRobotics discloses is robotic systems and single-use disposable handpieces, classified HIGH by disclosed size. Below: the full set from the latest 10-K — verbatim quotes, filing references, and a synthesis of what these exposures mean together.

Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.

Show full disclosure ▾

About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.

Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.

Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.

No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.

No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.

Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.

Methodology · Editorial policy & full disclaimer

Source: PROCEPT BioRobotics’s SEC Form 10-K filed view the filing on SEC EDGAR ↗

At a glance

Disclosed-size breakdown · 1 disclosed concentration

HIGH1
MEDIUM0
LOW0
Disclosed concentrations

Each card carries a disclosed-size chip (HIGH / MEDIUM / LOW — how large the exposure is as a share of revenue, not how dangerous it is) and a nature tag: Built-in(the company’s own model, geography, or products) or Outside party (an external customer, supplier, or distributor it relies on).

HIGHBuilt-inProduct / Revenue mix

robotic systems and single-use disposable handpieces

10-K Item 1A: 'substantially all of our revenue has been derived...from sales of our robotic systems and our accompanying single-use disposable handpieces'
SEC 10-K · filed Feb 2026
TrendMatrix Research · concentration synthesis

What these concentrations mean together

updated 2026-07-06

Procept BioRobotics' revenue base is concentrated by product line rather than by customer or geography: substantially all revenue is derived from sales of its robotic systems and the accompanying single-use disposable handpieces. This is a structural exposure — it reflects the company's business model rather than dependence on any single counterparty, supplier, or region. There is no disclosed customer, geographic, or supplier concentration in the filing to weigh against it. The practical implication is that the company's fortunes are tied almost entirely to continued adoption of the robotic platform and recurring handpiece consumption; any slowdown in procedure volume or system placements would flow directly through revenue with little offsetting diversification. Because this concentration is structural rather than a dependency on a specific customer or single-source input, it is unlikely to create an abrupt shock — it instead defines the shape of the investment case itself: a razor/razorblade model where growth is a function of installed base and utilization rather than a diversified revenue mix. Absent other disclosed exposures, this is the primary lens through which to read the company's concentration profile.

For the engine’s reasoning on PRCT’s current verdict — including which dimensions drove the score — see the per-dimension breakdown.

Industry peers · Medical Devices

Peer concentration profile

SymbolNameHIGHMEDIUMLOWTotal
AORTArtivion, Inc.4408
AVNSAvanos Medical, Inc.2013
ATECAlphatec Holdings, Inc.1102
ABTAbbott Laboratories1001
PRCTPROCEPT BioRobotics Corporation1001
AHCOAdaptHealth Corp.0000

Concentration counts reflect items disclosed in each peer’s most recent 10-K; disclosed-size classification uses TrendMatrix’s internal 10-K extraction taxonomy.

Concentration disclosures are extracted verbatim from SEC 10-K filings; the disclosed-size classification and the synthesis above are engine-derived. Size reflects how large each exposure is against fixed share thresholds (HIGH >50%, MEDIUM 25–50%, LOW <25% or an explicit diversification statement), not a judgment of how dangerous it is, and is not a buy/sell rating, a price target, or a view on the stock. Not a complete list of risk factors — see the full filing.

Home Stocks PRCT Concentration risk